Evaluation of homocystein and asymmetric dimethyl arginine levels in patients with coronary slow flow phenomenon

Yükleniyor...
Küçük Resim

Tarih

2019

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Akademiai Kiado Zrt

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Background: Previous studies have demonstrated that homocysteine and asymmetric dimethyl arginine (ADMA) levels were strongly associated with cardiovascular diseases including coronary artery disease. The aim of this study was to investigate the role of plasma homocysteine and ADMA levels in the pathogenesis of coronary slow flow (CSF) phenomenon. Methods: Twenty-three patients with CSF and 25 controls with normal coronary flow were included in this study. The quantitative measurement of coronary blood flow was performed using the thrombolysis in myocardial infarction frame count method. Plasma homocysteine and ADMA levels were determined using enzymatic assays from venous blood samples. Results: The patients with CSF had significantly higher plasma homocysteine levels than controls (16.2 +/- 7.6 vs. 12.2 +/- 2.2 mu M/L; p = 0.023). The uric acid levels were significantly higher in CSF group than controls (5.4 +/- 1.1 vs. 4.6 +/- 0.9 mg/dl; p = 0.011). Plasma ADMA levels were also higher in the CSF group; however, this was not statistically significant (0.6 +/- 0.1 vs. 0.5 +/- 0.2 mu M/L; p = 0.475). Conclusions: Increased homocysteine and uric acid levels may play an important role in the pathogenesis of CSF. Further large scale studies are required to determine the relationship between ADMA levels and CSF.

Açıklama

Anahtar Kelimeler

Asymmetric Dimethyl Arginine, Coronary Artery, Coronary Slow Flow, Endothelial Dysfunction, Homocystein

Kaynak

Interventional Medicine And Applied Science

WoS Q Değeri

N/A

Scopus Q Değeri

N/A

Cilt

11

Sayı

2

Künye

Demirci, E., Çelik, O., Kalçık, M., Bekar, L., Yetim, M., & Doğan, T. (2019). Evaluation of homocystein and asymmetric dimethyl arginine levels in patients with coronary slow flow phenomenon. Interventional Medicine and Applied Science, 11(2), 89-94.